Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms (Q37983083)

26 August 2017

Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms (English)

1 reference

26 August 2017

1 reference

Jamal Joudeh

1

1 reference

PubMed ID

22324354

26 August 2017

David Claxton

series ordinal

2

1 reference

PubMed ID

22324354

26 August 2017

language of work or name

English

0 references

publication date

11 February 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

1 reference

26 August 2017

21

1 reference

26 August 2017

3

1 reference

26 August 2017

363-373

1 reference

Bcl-2 family proteins and cancer

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Mimicking the BH3 domain to kill cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

BH3-mimetics--the solution to chemoresistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Identification of deficient mitochondrial signaling in apoptosis resistant leukemia cells by flow cytometric analysis of intracellular cytochrome c, caspase-3 and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Survivin and IAP proteins in cell-death mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.652302

10.1517/13543784.2012.652302

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22324354